These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 20417865

  • 1. Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer.
    Silva Soares EW, de Lima Santos SC, Bueno AG, Cavalli IJ, Cavalli LR, Fouto Matias JE, de Souza Fonseca Ribeiro EM.
    Cancer Genet Cytogenet; 2010 May; 199(1):24-30. PubMed ID: 20417865
    [Abstract] [Full Text] [Related]

  • 2. Alterations of the FHIT gene in breast cancer: association with tumor progression and patient survival.
    Ingvarsson S, Sigbjornsdottir BI, Huiping C, Jonasson JG, Agnarsson BA.
    Cancer Detect Prev; 2001 May; 25(3):292-8. PubMed ID: 11425271
    [Abstract] [Full Text] [Related]

  • 3. Detection of loss of heterozygosity at RAD51, RAD52, RAD54 and BRCA1 and BRCA2 loci in breast cancer: pathological correlations.
    Gonzalez R, Silva JM, Dominguez G, Garcia JM, Martinez G, Vargas J, Provencio M, España P, Bonilla F.
    Br J Cancer; 1999 Oct; 81(3):503-9. PubMed ID: 10507777
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Allelic loss at the 8p22 region as a prognostic factor in large and estrogen receptor negative breast carcinomas.
    Utada Y, Haga S, Kajiwara T, Kasumi F, Sakamoto G, Nakamura Y, Emi M.
    Cancer; 2000 Mar 15; 88(6):1410-6. PubMed ID: 10717624
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
    Yang Q, Nakamura M, Nakamura Y, Yoshimura G, Suzuma T, Umemura T, Shimizu Y, Mori I, Sakurai T, Kakudo K.
    Clin Cancer Res; 2002 Sep 15; 8(9):2890-3. PubMed ID: 12231533
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Loss of FHIT expression in breast cancer is correlated with poor prognostic markers.
    Arun B, Kilic G, Yen C, Foster B, Yardley DA, Gaynor R, Ashfaq R.
    Cancer Epidemiol Biomarkers Prev; 2005 Jul 15; 14(7):1681-5. PubMed ID: 16030101
    [Abstract] [Full Text] [Related]

  • 10. Frequent FHIT gene loss of heterozygosity in human papillomavirus-infected non-smoking female lung cancer in Taiwan.
    Wang J, Cheng YW, Wu DW, Chen JT, Chen CY, Chou MC, Lee H.
    Cancer Lett; 2006 Apr 08; 235(1):18-25. PubMed ID: 15935551
    [Abstract] [Full Text] [Related]

  • 11. FHIT gene in gastric cancer: association with tumour progression and prognosis.
    Noguchi T, Müller W, Wirtz HC, Willers R, Gabbert HE.
    J Pathol; 1999 Aug 08; 188(4):378-81. PubMed ID: 10440747
    [Abstract] [Full Text] [Related]

  • 12. Allelic deletion analysis of the FHIT gene predicts poor survival in non-small cell lung cancer.
    Burke L, Khan MA, Freedman AN, Gemma A, Rusin M, Guinee DG, Bennett WP, Caporaso NE, Fleming MV, Travis WD, Colby TV, Trastek V, Pairolero PC, Tazelaar HD, Midthun DE, Liotta LA, Harris CC.
    Cancer Res; 1998 Jun 15; 58(12):2533-6. PubMed ID: 9635574
    [Abstract] [Full Text] [Related]

  • 13. Loss of heterozygosity of the BRCA1 and FHIT genes in patients with sporadic breast cancer from Southern Brazil.
    Santos SC, Cavalli LR, Cavalli IJ, Lima RS, Haddad BR, Ribeiro EM.
    J Clin Pathol; 2004 Apr 15; 57(4):374-7. PubMed ID: 15047740
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of familial non-BRCA1/2 breast tumors by loss of heterozygosity and immunophenotyping.
    Oldenburg RA, Kroeze-Jansema K, Meijers-Heijboer H, van Asperen CJ, Hoogerbrugge N, van Leeuwen I, Vasen HF, Cleton-Jansen AM, Kraan J, Houwing-Duistermaat JJ, Morreau H, Cornelisse CJ, Devilee P.
    Clin Cancer Res; 2006 Mar 15; 12(6):1693-700. PubMed ID: 16551851
    [Abstract] [Full Text] [Related]

  • 16. Loss of heterozygosity at the BRCA1 locus in Tunisian women with sporadic breast cancer.
    Charef-Hamza S, Trimeche M, Ziadi S, Amara K, Gaddas N, Mokni M, Sriha B, Yacoubi T, Korbi S.
    Cancer Lett; 2005 Jun 28; 224(2):185-91. PubMed ID: 15914269
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Deletions of BRCA1/2 and p53 R248W gain-of-function mutation suggest impaired homologous recombination repair in fragile histidine triad-negative sebaceous gland carcinomas.
    Becker K, Goldberg M, Helmbold P, Holbach LM, Loeffler KU, Ballhausen WG.
    Br J Dermatol; 2008 Dec 28; 159(6):1282-9. PubMed ID: 18717684
    [Abstract] [Full Text] [Related]

  • 19. Loss of BRCA2 correlates with reduced long-term survival of sporadic breast cancer patients.
    Hampl JA, Hampl M, Reiss G, Koch R, Saeger HD, Schackert HK.
    Anticancer Res; 2004 Dec 28; 24(1):281-90. PubMed ID: 15015609
    [Abstract] [Full Text] [Related]

  • 20. Loss of heterozygosity in normal breast epithelial tissue and benign breast lesions in BRCA1/2 carriers with breast cancer.
    Cavalli LR, Singh B, Isaacs C, Dickson RB, Haddad BR.
    Cancer Genet Cytogenet; 2004 Feb 28; 149(1):38-43. PubMed ID: 15104281
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.